PMID- 7868248
OWN - NLM
STAT- MEDLINE
DCOM- 19950330
LR  - 20210526
IS  - 0019-9567 (Print)
IS  - 1098-5522 (Electronic)
IS  - 0019-9567 (Linking)
VI  - 63
IP  - 3
DP  - 1995 Mar
TI  - Immunopathological activities of extracellular products of Streptococcus mitis, 
      particularly a superantigenic fraction.
PG  - 785-93
AB  - Previously, we prepared extracellular products, fractions F-1 and F-2 of 
      Streptococcus mitis 108, an isolate from the tooth surface of an infant, and 
      showed that F-1 exhibited inflammatory cytokine-inducing activities. In the 
      present study, we present evidence that fraction F-2 induced human T-cell 
      proliferation in the presence of irradiated human peripheral blood mononuclear 
      cells and selectively activated T cells bearing V beta 2 and V beta 5.1 in the 
      T-cell receptor. F-1, on the other hand, stimulated human gingival fibroblasts to 
      support the T-cell proliferation in the same way as human gamma interferon or 
      Prevotella intermedia lipopolysaccharide (LPS). Fraction F-1 also primed gingival 
      fibroblasts to support the production of interleukin-2 and gamma interferon by 
      the T cells upon stimulation with F-2. Human gingival fibroblasts stimulated with 
      fraction F-1, like those stimulated by P. intermedia LPS and human gamma 
      interferon, exhibited human leukocyte antigen (HLA)-DR mRNA expression and cell 
      surface HLA-DR molecules as detected by enzyme-linked immunosorbent assay. An 
      anti-HLA-DR monoclonal antibody inhibited T-cell proliferation in response to 
      F-2, probably through inactivating the accessory function of HLA-DR-bearing 
      fibroblasts. T cells activated with F-2 in the presence of irradiated peripheral 
      blood mononuclear cells exhibited definite cytotoxic effects against fibroblasts 
      and squamous carcinoma cells originating from human oral tissues. These findings 
      are strongly suggestive of an association of extracellular products of viridans 
      streptococci with pathogenesis of oral mucosal diseases, particularly those 
      disorders in gingiva which are accompanied by heavy infiltration of T cells.
FAU - Matsushita, K
AU  - Matsushita K
AD  - Department of Microbiology and Immunology, Kagoshima University Dental School, 
      Japan.
FAU - Fujimaki, W
AU  - Fujimaki W
FAU - Kato, H
AU  - Kato H
FAU - Uchiyama, T
AU  - Uchiyama T
FAU - Igarashi, H
AU  - Igarashi H
FAU - Ohkuni, H
AU  - Ohkuni H
FAU - Nagaoka, S
AU  - Nagaoka S
FAU - Kawagoe, M
AU  - Kawagoe M
FAU - Kotani, S
AU  - Kotani S
FAU - Takada, H
AU  - Takada H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Bacterial)
RN  - 0 (Cytokines)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
RN  - 0 (Superantigens)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology
MH  - Antigens, Bacterial/*immunology
MH  - Cells, Cultured
MH  - Cytokines/biosynthesis
MH  - Cytotoxicity, Immunologic
MH  - Fibroblasts/immunology/pathology
MH  - Gingiva/cytology/*immunology/pathology
MH  - HLA-DR Antigens/biosynthesis/genetics/immunology
MH  - Histocompatibility Antigens Class II/immunology
MH  - Humans
MH  - Immunohistochemistry
MH  - Lipopolysaccharides/immunology
MH  - Lymphocyte Activation/immunology
MH  - Prevotella intermedia/immunology
MH  - RNA, Messenger/analysis
MH  - Receptors, Antigen, T-Cell, alpha-beta/genetics/immunology
MH  - Streptococcus/*immunology
MH  - Superantigens/*immunology
MH  - T-Lymphocytes/*immunology
PMC - PMC173071
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
PMCR- 1995/03/01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PHST- 1995/03/01 00:00 [pmc-release]
AID - 10.1128/iai.63.3.785-793.1995 [doi]
PST - ppublish
SO  - Infect Immun. 1995 Mar;63(3):785-93. doi: 10.1128/iai.63.3.785-793.1995.